Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.9313
USD
|
+1.68%
|
|
+6.90%
|
+57.85%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
731
|
420.6
|
224.3
|
78.84
|
17.6
|
28.9
|
-
|
-
|
Enterprise Value (EV)
1 |
731
|
420.6
|
224.3
|
78.84
|
17.6
|
28.9
|
28.9
|
28.9
|
P/E ratio
|
-31.7
x
|
-
|
-6.16
x
|
-2.23
x
|
-0.56
x
|
-0.86
x
|
-0.76
x
|
-0.68
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
24.7
x
|
14
x
|
16
x
|
4.09
x
|
2.06
x
|
2.71
x
|
1.6
x
|
1.22
x
|
EV / Revenue
|
24.7
x
|
14
x
|
16
x
|
4.09
x
|
2.06
x
|
2.71
x
|
1.6
x
|
1.22
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
68,118,185
x
|
-10,808,518
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,236
|
20,318
|
22,751
|
22,786
|
29,829
|
31,036
|
-
|
-
|
Reference price
2 |
38.00
|
20.70
|
9.859
|
3.460
|
0.5900
|
0.9313
|
0.9313
|
0.9313
|
Announcement Date
|
3/3/20
|
3/4/21
|
3/7/22
|
3/7/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
29.56
|
30.11
|
13.98
|
19.28
|
8.548
|
10.65
|
18.04
|
23.65
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-19.15
|
-12.62
|
-34.27
|
-35.08
|
-36.88
|
-35.93
|
-36.82
|
-43.47
|
Operating Margin
|
-64.78%
|
-41.89%
|
-245.21%
|
-181.93%
|
-431.49%
|
-337.23%
|
-204.12%
|
-183.79%
|
Earnings before Tax (EBT)
1 |
-20.58
|
-14.34
|
-36.26
|
-35.33
|
-27.62
|
-30.38
|
-38.02
|
-42.87
|
Net income
1 |
-20.58
|
-0.582
|
-36.26
|
-35.33
|
-27.62
|
-37.17
|
-38.02
|
-42.87
|
Net margin
|
-69.6%
|
-1.93%
|
-259.46%
|
-183.23%
|
-323.16%
|
-348.9%
|
-210.76%
|
-181.26%
|
EPS
2 |
-1.200
|
-
|
-1.600
|
-1.550
|
-1.050
|
-1.083
|
-1.230
|
-1.360
|
Free Cash Flow
|
10.73
|
-38.91
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
36.3%
|
-129.23%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/20
|
3/4/21
|
3/7/22
|
3/7/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
2.165
|
7.297
|
1.915
|
2.076
|
11.98
|
3.315
|
2.054
|
2.081
|
1.744
|
2.669
|
2.725
|
2.825
|
2.925
|
3.13
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.458
|
-6.512
|
-10.37
|
-11.09
|
-2.132
|
-11.5
|
-11.02
|
-10.05
|
-9.557
|
-6.254
|
-6.336
|
-6.236
|
-7.636
|
-8.93
|
Operating Margin
|
-436.86%
|
-89.24%
|
-541.31%
|
-534.01%
|
-17.8%
|
-346.85%
|
-536.61%
|
-482.99%
|
-547.99%
|
-234.32%
|
-232.51%
|
-220.74%
|
-261.06%
|
-285.27%
|
Earnings before Tax (EBT)
1 |
-9.977
|
-7.008
|
-10.84
|
-11.55
|
-2.471
|
-10.47
|
-11.99
|
-11.18
|
-3.015
|
-1.441
|
-6.646
|
-6.546
|
-7.946
|
-9.24
|
Net income
1 |
-9.977
|
-7.008
|
-10.84
|
-11.55
|
-2.471
|
-10.47
|
-11.99
|
-11.18
|
-3.015
|
-1.441
|
-6.646
|
-6.546
|
-7.946
|
-9.24
|
Net margin
|
-460.83%
|
-96.04%
|
-566.16%
|
-556.41%
|
-20.63%
|
-315.81%
|
-583.59%
|
-537.29%
|
-172.88%
|
-53.99%
|
-243.89%
|
-231.72%
|
-271.66%
|
-295.18%
|
EPS
2 |
-0.4000
|
-0.3000
|
-0.5000
|
-0.5000
|
-0.1000
|
-0.4600
|
-0.5000
|
-0.4600
|
-0.1100
|
-0.0500
|
-0.2200
|
-0.1850
|
-0.2300
|
-0.2700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
3/7/22
|
5/4/22
|
8/4/22
|
11/2/22
|
3/7/23
|
5/8/23
|
8/9/23
|
11/13/23
|
3/27/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
10.7
|
-38.9
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.16
|
0.21
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.52%
|
0.69%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/20
|
3/4/21
|
3/7/22
|
3/7/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
0.9313
USD Average target price
6.75
USD Spread / Average Target +624.79% Consensus |
1st Jan change
|
Capi.
|
---|
| +57.85% | 28.9M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|